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| INTRODUCTION

Protein S (PS) acts as a cofactor for activated protein C (APC)
and tissue factor pathway inhibitor (TFPI). PS enhances the APCmediated inactivation of coagulation factors Va (FVa) and VIIIa, and also the TFPI-mediated inhibition of coagulation factor Xa (FXa). [1] [2] [3] [4] Furthermore, the TFPI cofactor activity of PS was enhanced in the presence of coagulation factor V (FV).
5 PS deficiency is a risk factor for developing venous thromboembolism (VTE) FVa more than 10-fold, but inhibits the proteolysis at Arg 506 of FVa 3~4-fold. 6 In plasma, the APC cofactor activity of PS is inhibited by proteolytic cleavage in the TSR.
1,2
We and others previously identified a missense mutation (c.586A>G, p.K196E, formerly known as PS Tokushima or K155E in the mature protein numbering) in the PROS1 gene as a risk factor for VTE, with odds ratios between 3.74 and 8.56. [7] [8] [9] [10] [11] The frequency of the mutant E-allele in the Japanese general population is approximately 0.009. 12, 13 This mutation is present only in the Japanese population. [13] [14] [15] PS K196E knock-in mice had decreased APC cofactor activity in plasma and were more susceptible to deep vein thrombosis compared with wild-type (WT) mice. 16 Two studies analyzed the function of recombinant PS K196E mutant (PS-E) and WT (PS-K) expressed in mammalian cells. 17, 18 One showed that PS-E failed to interact with APC and had no APC cofactor activity. 17 In contrast, the other demonstrated that the APC cofactor activity of PS-E decreased to 58% of that of PS-K. 18 The discrepancy between these studies may be partly due to differences in preparation methods of the recombinant proteins: the former used partially purified recombinant proteins expressed in baby hamster kidney cells, and the latter used conditioned media containing recombinant proteins expressed in human embryo kidney 293 cells. In addition, these studies did not investigate the TFPI cofactor activity of PS-E.
The aim of this study was to reevaluate and further elucidate the molecular basis of the thrombophilic phenotype of the PS-E mutant.
We highly purified recombinant human PS-K and PS-E expressed by
Chinese hamster ovary (CHO) cells and analyzed their anticoagulant functions. Our data indicate that the PS K196E mutation impairs the protein's function as an APC cofactor but not as a TFPI cofactor. 
| MATERIAL S AND ME THODS
| PS expression, purification, and quantification
| Phospholipid vesicle preparation
Synthetic phospholipids (Avanti Polar Lipids, Alabaster, AL) 1,2-dio leoyl-sn-glycero-3-phosphoserine (DOPS), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-dioleoyl-sn-glycero-3-phospho ethanolamine (DOPE) in chloroform were blended, and chloroform was evaporated under a nitrogen stream. The phospholipids were resuspended in TBS and mixed vigorously for 1 hour with shaking.
Phospholipid vesicles were prepared by extrusion using an Avanti
Mini-Extruder (Avanti Polar Lipids). Clotting was initiated by addition of CaCl 2 , and clotting time was measured. The APC cofactor activity was evaluated based on the slope of a linear increase in clotting time. The remaining FXa activity obtained in the absence of PS was considered as 100%.
| PS-dependent APC-mediated FVa
HNBSACa 2+ buffer (25 mmol L −1 N-[2-hydroxyethyl]piperazine-N′-2-ethanesulfonic acid, 150 mmol L −1 NaCl, 5 mmol L −1 CaCl
| PS-dependent TFPI-mediated FXa
| Binding of PS to C4BP
We prepared and purified a recombinant fragment (Glu 
| RESULTS AND DISCUSSION
In this study, we first examined whether the PS K196E mutation affects the protein's APC cofactor activity by performing a clottingbased assay and a FVa inactivation assay. In the clotting-based assay,
PS-E showed 41.4% ± 3.1% APC cofactor activity compared with PS-K ( Figure 1A ), which is in agreement with a previous report 18 and a study on recombinant mouse PS-E. 16 In the FVa inactivation assay, an approximately twofold concentration of PS-E, as compared to PS-K, was required to achieve 50% inactivation of FVa activity (PS-K Figure 1B) . Thus, PS-E had a reduced ability to enhance APC-mediated inactivation of FVa. showed modestly reduced APC cofactor activity. 22 We have previously obtained monoclonal antibodies specific to the PS-E in the native form, indicating the surface presentation of the Lys 196 residue. 23 We next examined whether the PS K196E mutation affects its The APC cofactor activity of PS is reduced by its binding to C4BP
and by the proteolytic cleavage in the TSR by thrombin. 1, 2 In the present study, PS-K and PS-E showed equal binding to the β chain of C4BP (K dapp :
; Figure 3 ). This is consistent with the observation that the SHBG-like domain of PS interacts with the β chain of C4BP 24 and that the plasma free PS level of a homozygous E-allele carrier is within normal limits. 18 Meanwhile, the TSR of PS is involved in the interaction with APC and the Gla domain for phospholipid binding, and the cleavage of the TSR by thrombin results in the reduction of APC cofactor activity. 25 We demonstrated that PS-K and PS-E were equally cleaved by thrombin (Figure 4 ). Taken together, these data show that the K196E mutation does not affect the loss of function of PS caused by its binding to C4BP or by thrombin-dependent cleavage.
In conclusion, the present study reveals that the K196E mutation impairs the molecular function of PS as an APC cofactor but not as a TFPI cofactor. The impaired APC cofactor activity of the PS K196E mutant causes an increased risk of VTE in E-allele carriers.
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